Compare
Century Therapeutics, Inc. vs ImmunityBio, Inc. vs Agenus Inc vs Atara Biotherapeutics, Inc.
| Latest fiscal year | Century Therapeutics, Inc. IPSC | ImmunityBio, Inc. IBRX | Agenus Inc AGEN | Atara Biotherapeutics, Inc. ATRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $109.16M | $113.29M | $114.20M | $120.77M |
| Revenue growth (YoY) | n/m | +668.3% | +10.4% | -6.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -15.8% | -226.0% | -17.7% | 29.7% |
| Net margin | -8.8% | -310.2% | -2.7% | 27.1% |
| Net income | -$9.58M | -$351.40M | -$3.08M | $32.69M |
| EPS (Diluted) | -$0.14 | -$0.38 | $0.00 | $2.57 |
| Operating cash flow | -$103.88M | -$304.94M | -$77.19M | -$50.94M |
| Free cash flow | -$104.72M | -$308.78M | -$77.20M | -$50.94M |
| Cash & equivalents | $61.85M | $88.33M | $3.00M | $8.48M |
| Total assets | $223.70M | $501.90M | $226.80M | $20.23M |
| Total liabilities | $64.77M | $1.00B | n/a | $58.74M |
| Shareholders' equity | $158.94M | -$500.47M | -$271.11M | -$38.50M |
| Return on year-end equity | -6.0% | n/a | n/a | n/a |
| Shares outstanding | 87.52M | 1.01B | 35.32M | 7.32M |
Revenue, most recent five fiscal years
| Fiscal year | Century Therapeutics, Inc. | ImmunityBio, Inc. | Agenus Inc | Atara Biotherapeutics, Inc. |
|---|---|---|---|---|
| Latest | $109.16M Ended 2025-12-31 | $113.29M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $120.77M Ended 2025-12-31 |
| 1 year earlier | $6.59M Ended 2024-12-31 | $14.74M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $128.94M Ended 2024-12-31 |
| 2 years earlier | $2.23M Ended 2023-12-31 | $622.0K Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $8.57M Ended 2023-12-31 |
| 3 years earlier | $5.20M Ended 2022-12-31 | $240.0K Ended 2022-12-31 | $98.02M Ended 2022-12-31 | $63.57M Ended 2022-12-31 |
| 4 years earlier | n/a | $934.0K Ended 2021-12-31 | $295.67M Ended 2021-12-31 | n/a |